EVR and EPO for Liver Transplant Tolerance

NCT06832189

Status	RECRUITING
Phase	Phase 1
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (12)

- Subject must be able to understand and provide informed consent
- years post-liver transplant
- Tacrolimus-containing maintenance immunosuppression (IS) regimen without corticosteroid. Mycophenolate mofetil (MMF) dose must be \<=2000 mg daily or mycophenolic acid (MPA) dose\<=1440 mg daily (if on MMF or MPA). Tacrolimus level must be \<8 ng/ml on the 2 most recent laboratory results within 3 months.
- Gamma glutamyl transferase (GGT) and alanine transaminase (ALT) \<= upper limit of normal (ULN)
- Estimated glomerular filtration rate (GFR) \>=40 mL/min/1.73 m\^2 using the CKD-EPI 2021 equation

... and 7 more (see full listing online)

Exclusion (35)

- Inability of a subject to comply with study protocol
- Any medical condition requiring chronic systemic corticosteroid, e.g., severe reactive airways disease. Use of inhaled steroids is not an exclusion
- Autoimmune cause of liver disease (including autoimmune hepatitis (AIH), primary sclerosing cholangitis, primary biliary cirrhosis)
- Diagnosis of rejection within 52 weeks prior to screening
- Donor human leukocyte antigen (HLA) typing unavailable or inadequate for assigning donor-specific antibody (DSA)

... and 30 more (see full listing online)

Locations (3 total)

University of California San Francisco School of Medicine, San Francisco, California, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States